(NYSE: ANRO) Alto Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 62.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Alto Neuroscience's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ANRO's revenue for 2028 to be $503,541,599, with the lowest ANRO revenue forecast at $503,541,599, and the highest ANRO revenue forecast at $503,541,599. On average, 2 Wall Street analysts forecast ANRO's revenue for 2029 to be $1,845,507,034, with the lowest ANRO revenue forecast at $1,683,886,424, and the highest ANRO revenue forecast at $2,007,127,644.
In 2030, ANRO is forecast to generate $4,417,521,722 in revenue, with the lowest revenue forecast at $689,797,847 and the highest revenue forecast at $9,454,941,053.